<DOC>
	<DOCNO>NCT02552381</DOCNO>
	<brief_summary>The purpose study assess fibrin structure marker plasma cancer patient , treat treat LMWH therapeutic dos , order determine venous thromboembolic risk . The occurrence thromboembolic event patient without treatment patient LMWH treatment therapeutic dos record , depend location type cancer , metastasis , treatment cancer .</brief_summary>
	<brief_title>Evaluation Fibrin Structure Marker Cancer Patients Treated Not Treated With LMWH</brief_title>
	<detailed_description>Rationale . Venous thromboembolism ( VTE ) major complication often encounter oncology onco-hematology , difficult handle . It involve activation coagulation generation fibrin plasmin angiogenesis activation . Low molecular weight heparin ( LMWH ) use treat cancer associate thrombosis . Furthermore , could inhibitory effect tumor progression . International recommendation treatment prophylaxis disease allow well management VTE patient cancer . Its prevalence high , occur 15-20 % patient . It remain second lead cause death cancer . LMWH therapeutic dosage least three month preferably six month without oral bridge reference treatment VTE , show 50 % reduction risk recurrent thromboembolism without increase hemorrhagic risk . In case VTE recurrence LMWH treatment , dose increase 10 % . Preliminary result suggest fibrin structure marker would predict hemorrhagic thromboembolic risk , show LMWH dose-dependent effect fibrin structure . This marker evaluate tool guide treatment VTE LMWH patient cancer . Main objective . To assess fibrin structure marker plasma cancer patient , treat treat LMWH therapeutic dos , determine venous thromboembolic risk . The occurrence thromboembolic event patient without treatment recurrent thromboembolic event patient LMWH treatment therapeutic dos study , depend location type cancer , metastasis , treatment cancer . Patients . At least 100 adult patient 18 year types malignancy document therapeutic treatment LMWH thromboembolic event . They monitor every month consultation hospitalization Internal Medicine Department . The patient prophylaxis LMWH also include classified group untreated patient thromboembolic event . Will include : patient sepsis , severe infection , pneumonia , surgery , suspect thromboembolic event relate catheter implantation , vitamin K antagonist ( VKA ) progress , impossible follow-up . The study conduct compliance French regulation ethic approval , authorization process personal data ( Commission Nationale de l'Informatique et de Libert√©s , 8 , rue Vivienne CS 30223 75083 Paris Cedex 02 ) receipt number 1867686 v 0 , date 18 June 2015 . Reference algorithm . Patients support diagnosis specific treatment cancer ( without metastasis ) , accord daily practice . The baseline risk score Khorana score clinical probability , base clinical criterion . A thromboembolic event diagnose accord standard imaging criterion ( spiral compute tomography CT , proximal low limb venous compression ultrasonography US ) clinicians knowledge result fibrin structure marker . Biological parameter study . The following test carry frozen citrate plasma serum , without knowledge clinical data conclusion diagnostic thromboembolic event : - Structure fibrin dose baseline every month patient , one site , use prototype assay - Anti-FXa activity measure baseline every month patient treat LMWH therapeutic dos , - sP selectin platelet activation , heparanase TFPI coagulation activation , DDimers PAI-1 fibrinolysis resistance , measure baseline every 3 month patient .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>patient nonopposition participate evaluation patient Internal Medicine Department patient affect types malignancy , treat LMWH patient treat VKA recent surgery ( within one month ) patient condition know cause coagulation activation status cancer ( sepsis , pneumonia , .. )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Thromboembolic event</keyword>
	<keyword>Fibrin Structure</keyword>
	<keyword>LMWH</keyword>
</DOC>